Protagonist Therapeutics Inc.

PTGX

Held by 9 specialist biotech funds

High Convergence

9 funds opened new positions. Next phase2 readout (PTG-300): Jul 2020. Short interest: 15.7% of float.

BiotechnologyCEO: Dinesh V. PatelIPO: 2016Website ↗

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Insider Signals

MOLINA ARTURO MDChief Medical OfficerSaleMar 27, 2026SEC Filing →

Shares: 15,000Value: $1,571,850Price: $104.79

Insider Sale — PTGX — CMO Molina, $1.57M

CMO sold 15,000 shares at $104.79, a meaningful dollar amount though insider sales at elevated prices are often liquidity/diversification-driven rather than bearish signals, particularly for a C-suite officer with concentrated equity exposure. Worth noting PTGX has had a strong run on rusfertide progress toward potential approval in polycythemia vera, so this could simply be harvesting gains near highs. Monitor for additional insider sales or any clustering among other executives, which would shift this from routine to potentially informative.

Ali AsifChief Financial OfficerSaleMar 27, 2026SEC Filing →

Shares: 24,765Value: $2,581,503.6Price: $104.24

Insider Transaction Note — PTGX

CFO Ali Asif sold ~$2.6M in shares at $104.24, a meaningful disposal that warrants monitoring but requires context: CFO-level sales often reflect diversification, tax planning, or liquidity needs rather than bearish conviction, particularly after PTGX's significant price appreciation. Worth checking whether this aligns with a 10b5-1 pre-scheduled plan, which would substantially reduce the informational signal. On its own, a single CFO sale is low-to-moderate signal — it becomes more meaningful if clustered with additional insider dispositions in the near term.

SELICK HAROLD EOtherSaleMar 27, 2026SEC Filing →

Shares: 24,000Value: $2,520,000Price: $105.00

Insider Sale – Protagonist Therapeutics (PTGX) – Harold Selick, $2.52M

Selick, a non-executive insider, sold 24,000 shares at $105, a meaningful liquidation at elevated price levels for a mid-cap biotech. While insider sales are lower-signal than purchases — often driven by diversification, tax planning, or liquidity needs — the size warrants monitoring, particularly if other insiders follow. Check whether this was executed under a pre-planned 10b5-1 trading plan, which would substantially reduce the informational content of the transaction.

Protagonist Therapeutics Inc.

Signal Score

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent Insider Activity

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research